Guardant Health, Inc.
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics. Its products are used to help detect cancer earlier, monitor recurrence, and guide treatment selection, with a growing mix of clinical testing, biopharma services, and screening revenue.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBlood and tissue tests used by clinicians for therapy selection, monitoring, and recurrence detection.
Shield screening tests sold for early cancer detection in average-risk populations.
Companion diagnostic development, regulatory support, monitoring, data services, and referral services for drug developers.
Technology licensing and other ancillary revenue streams tied to proprietary sequencing and analytics.
Products
Reported · share of revenue- Oncology69.6 %
- Biopharma Data21.4 %
- Screening8.1 %
- Licensing Other0.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Customers include oncologists, hospitals, cancer centers, research institutions, and patients who need actionable cancer testing across the care continuum. A second major customer group is biopharmaceutical companies, which use Guardant’s tests and data to support clinical studies, companion diagnostics, and regulatory programs. Payers and government programs are economically important because reimbursement determines adoption and realized revenue for clinical and screening tests.
Hospitals, cancer centers, and physicians order Guardant tests to guide therapy selection and monitor disease.
Drug developers buy companion diagnostic, monitoring, and data services to support trials and approvals.
Average-risk individuals and their clinicians use Shield for early cancer detection when coverage is available.
Medicare, Medicare Advantage, and VA coverage determine reimbursement and patient access for tests.
Strategy
Guardant is expanding from advanced cancer testing into earlier-stage detection and broader multi-modal biology through its Smart Platform. Management is also pushing commercial scale by widening payer coverage, deepening biopharma relationships, and expanding lab capacity and partner access to support growth.
Screening opens a much larger addressable market than advanced oncology testing and depends on reimbursement and physician adoption.
More tests across therapy selection and recurrence monitoring increase share of wallet across the cancer care continuum.
Biopharma relationships diversify revenue and monetize Guardant’s data, assays, and regulatory expertise.
The Smart Platform and AI analytics are intended to create differentiated next-generation tests.
Geography
Q1/2026The business is centered in the United States, where reimbursement from Medicare, private payers, and the VA is critical to commercial adoption. Guardant also uses strategic relationships with cancer centers, distributors, and laboratory partners in Europe and Asia to support international commercialization, including approved activity in Japan.
Share of the revenue the company reports by geography.
Risks
Guardant remains loss-making and depends on continued revenue growth, reimbursement expansion, and access to capital to fund commercialization and R&D. Its business is also exposed to payer coverage risk, biopharma customer concentration, regulatory approvals, and supply-chain dependence on specialized sequencing equipment and services.
- Ongoing operating lossesImpact: HighLikelihood: High
The company has a long history of losses and must keep investing in clinical studies, sales, and lab capacity before profitability is reached.
Exposure: Cash burn and financing needs
- Payer coverage and reimbursement riskImpact: HighLikelihood: High
Revenue depends on Medicare, private payer, and government reimbursement decisions for clinical and screening tests.
Exposure: Oncology and Shield screening revenue
- Supplier and lab operations disruptionImpact: HighLikelihood: Medium
The company relies on limited or sole suppliers, including Illumina for sequencers and maintenance.
Exposure: Testing throughput and service continuity
- Regulatory and approval riskImpact: MediumLikelihood: Medium
New tests and international commercialization depend on FDA and foreign regulatory approvals.
Exposure: Product launches and Japan/other markets
- Biopharma customer concentrationImpact: MediumLikelihood: Low
A limited number of biopharma customers can materially affect revenue if programs end or are delayed.
Exposure: Biopharma and data revenue
Accounting
Judgemental itemsClinical and screening revenue is based on expected collections, so payer behavior can change reported revenue timing and amount.
Impact: Affects top-line growth and gross margin comparability
Management says G&A expense has historically fluctuated significantly due to equity awards.
Impact: Can materially affect operating loss and non-cash expense
As test volume grows, working capital balances may increase and require judgment on collectability and obsolescence.
Impact: Affects cash conversion and balance sheet quality
The company has funded operations with equity, convertible notes, and revenue, so liquidity planning remains important.
Impact: Influences dilution and capital structure
Similar listed companies
Publicly listed companies with a comparable business focus.
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
GRAIL, Inc.
GRAL · Services-Medical Laboratories
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Pliant Therapeutics, Inc
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Labcorp Holdings Inc
LH · Services-Medical Laboratories
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Last updated: 24/09/2026